At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Retinoic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Skin disorders
Most Recent Events
- 09 Dec 1999 New profile
- 09 Dec 1999 Preclinical development for Cancer in USA (Unknown route)
- 09 Dec 1999 Preclinical development for Skin disorders in USA (Unknown route)